Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 4/20 | 1.00 |
| ▸ | SRD5A1 | P18405 | 2/20 | 1.00 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | FLT3 | P36888 | 1/20 | 0.55 |
| ▸ | CTSV | O60911 | 2/20 | 0.54 |
| ▸ | CTSL | P07711 | 2/20 | 0.54 |
| ▸ | PDE4A | P27815 | 1/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.50 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7169748 | 1.00 | SRD5A2 (1.00) | SRD5A2SRD5A1RXFP1HPGDKDM4E | |
| SCHEMBL7174812 | 0.94 | SRD5A2 (0.88) | SRD5A2SRD5A1RXFP1HPGDKDM4E | |
| SCHEMBL7738120 | 0.90 | SRD5A2 (0.82) | SRD5A2SRD5A1RXFP1HPGDKDM4E | |
| SCHEMBL5829229 | 0.90 | SRD5A2 (0.82) | SRD5A2SRD5A1RXFP1HPGDKDM4E | |
| SCHEMBL7159304 | 0.90 | SRD5A2 (0.82) | SRD5A2SRD5A1RXFP1HPGDKDM4E | |
| SCHEMBL5701889 | 0.90 | SRD5A2 (0.82) | SRD5A2SRD5A1RXFP1HPGDKDM4E | |
| SCHEMBL7201495 | 0.87 | SRD5A2 (0.77) | SRD5A2SRD5A1RXFP1HPGDKDM4E | |
| SCHEMBL5702163 | 0.86 | SRD5A2 (0.76) | SRD5A2SRD5A1RXFP1HPGDKDM4E | |
| SCHEMBL5701857 | 0.86 | SRD5A2 (0.76) | SRD5A2SRD5A1RXFP1HPGDKDM4E | |
| SCHEMBL187522 | 0.86 | SRD5A2 (0.76) | SRD5A2SRD5A1RXFP1HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1451185-B1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2014-08-06 | — | — | EP | disclosed |
| EP-1633746-B1 | NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-07-28 | — | — | EP | disclosed |
| US-20090069565-A1 | NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-03-12 | — | — | US | disclosed |
| US-7196103-B2 | Indole derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-03-27 | — | — | US | disclosed |
| EP-1633746-A1 | NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-03-15 | — | — | EP | disclosed |
| US-6989384-B2 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. (US) | 2006-01-24 | — | — | US | disclosed |
| US-6906084-B2 | Indole derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-06-14 | — | — | US | disclosed |
| EP-1042287-B1 | INDOLE DERIVATIVES AS INHIBITORS OF FACTOR XA | AVENTIS PHARMA GMBH (DE) | 2005-04-20 | — | — | EP | disclosed |
| US-20050080121-A1 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. | 2005-04-14 | — | — | US | disclosed |
| US-20050043302-A1 | New indole derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-02-24 | — | — | US | disclosed |
| US-20020061916-A1 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. | 2002-05-23 | — | — | US | disclosed |
| WO-2002034718-A1 | AMIDE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2002-05-02 | — | — | WO | disclosed |
| US-6337344-B1 | ANTICOAGULANTS AND ENZYME INHIBITORS FOR CARDIOVASCULAR DISORDERS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-01-08 | — | — | US | disclosed |
| WO-2001096297-A2 | ANTIPICORNAVIRAL COMPOUNDS AND COMPOSITIONS, THEIR PHARMACEUTICAL USES, AND MATERIALS FOR THEIR SYNTHESIS | AGOURON PHARMACEUTICALS, INC. (US) | 2001-12-20 | — | — | WO | disclosed |
| US-6214856-B1 | TREATING NEURODEGENERATIVE DISORDERS, E.G., ALZHEIMER'S DISEASE, STROKES, TRAUMATIC BRAIN INJURY; ANTIISCHEMIC AGENTS; MUSCULAR DYSTROPHY; ALSO CATARACTS; PLATELET AGGREGATION | SMITHKLINE BEECHAM CORPORATION | 2001-04-10 | — | — | US | disclosed |
| EP-1018878-A4 | NOVEL INDOLECARBOXAMIDES, PHARMACEUTICAL COMPOSITIONS AND METHODSOF INHIBITING CALPAIN | SMITHKLINE BEECHAM CORP (US) | 2001-01-10 | — | — | EP | disclosed |
| EP-1042287-A1 | INDOLE DERIVATIVES AS INHIBITORS OF FACTOR XA | Aventis Pharma Deutschland GmbH (DE) | 2000-10-11 | — | — | EP | disclosed |
| EP-1018878-A1 | NOVEL INDOLECARBOXAMIDES, PHARMACEUTICAL COMPOSITIONS AND METHODSOF INHIBITING CALPAIN | SmithKline Beecham Corporation (US) | 2000-07-19 | — | — | EP | disclosed |
| WO-1999033800-A1 | INDOLE DERIVATIVES AS INHIBITORS OR FACTOR XA | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 1999-07-08 | — | — | WO | disclosed |
| WO-1998041092-A1 | NOVEL INDOLECARBOXAMIDES, PHARMACEUTICAL COMPOSITIONS AND METHODSOF INHIBITING CALPAIN | SMITHKLINE BEECHAM CORPORATION (US) | 1998-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069565-A1 | NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS | F12, F5, F2 | SRD5A2 1571/4885SRD5A1 1267/4885RXFP1 44/4885 |
| US-20050080121-A1 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | PRCP, RNPEP, SARNP | SRD5A2 801/4885SRD5A1 718/4885RXFP1 3848/4885 |
| US-20020061916-A1 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | PRCP, RNASEL, RNASEH1 | SRD5A2 839/4885SRD5A1 703/4885RXFP1 3772/4885 |
| US-20050043302-A1 | New indole derivatives as factor Xa inhibitors | F12, F5, F2 | SRD5A2 1817/4885SRD5A1 1516/4885RXFP1 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.